Lieke J. van Vugt

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

J.M.P.A. van den Reek, Lieke J. van Vugt, Martijn B. A. van Doorn et al. · Acta Dermato Venereologica · 2018 · 62 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis

Selma Atalay, J.M.P.A. van den Reek, Alfons A den Broeder et al. · JAMA Dermatology · 2020 · 52 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Response to <scp>IL</scp>‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the <scp>IL</scp>‐17A gene: results from a multicentre study of four European psoriasis cohorts

Lieke J. van Vugt, J.M.P.A. van den Reek, Evelyn Meulewaeter et al. · Journal of the European Academy of Dermatology and Venereology · 2019 · 24 citations · Full text

Medicine, Immunology, Pharmacology +17

Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial

Selma Atalay, J.M.P.A. van den Reek, Lieke J. van Vugt et al. · BMC Dermatology · 2017 · 21 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice

Semra Atalay, L. S. van der Schoot, L. M. D. Vandermaesen et al. · Acta Dermato Venereologica · 2021 · 13 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16